Last reviewed · How we verify
NCT06637280
High - Flow Nasal Cannula Versus Conventional Nasal Cannula During Endobronchial Ultrasound Procedure
NA trial testing High - flow nasal cannula in Hypoxemia During EBUS Bronchoscopy in 150 participants. Currently enrolling.
1 November 2024
Quick facts
| Lead sponsor | The University Clinic of Pulmonary and Allergic Diseases Golnik |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 150 |
| Start date | 1 March 2024 |
| Primary completion | 1 November 2024 |
| Estimated completion | 1 November 2024 |
| Sites | 4 locations across Portugal, Croatia, Slovenia, Greece |
Drugs / interventions tested
- High - flow nasal cannula
- Standard nasal cannula
Conditions studied
- Hypoxemia During EBUS Bronchoscopy — all drugs for Hypoxemia During EBUS Bronchoscopy →
Sponsor
The University Clinic of Pulmonary and Allergic Diseases Golnik
Who can join
18 and older, any sex, with Hypoxemia During EBUS Bronchoscopy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
EBUS bronchoscopy is performed in most centers under local anesthesia and moderate sedation. Both the bronchoscopy itself and the sedation can lead to decreased ventilation and a drop in oxygen saturation in the body. Typically, oxygen is administered during the procedure via a nasal cannula at a flow rate of 6l/min. The aim of the study is to compare a new method - a nasal cannula with high flow - to the standard cannula. The primary objective is to demonstrate that the new method is more effective at preventing desaturation during the procedure. Patients will be randomized into two groups before bronchoscopy and monitored. The bronchoscopy will be performed in the same way for both groups. The only difference between the groups will be in the method of oxygen administration during EBUS bronchoscopy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06637280
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The University Clinic of Pulmonary and Allergic Diseases Golnik trials
Trials by the same sponsor.
- NCT05907577 — Early Detection of Lung Cancer With Machine Learning Based on Routine Clinical Investigations · unknown
- NCT04716088 — Rapid Antigen Testing for SARS-CoV-2 Among Healthcare Workers to Prevent Spread of COVID-19 · completed
- NCT04679428 — Immunological Characteristics of COVID-19 Patients · unknown
- NCT06207500 — Evaluation of Pharmacist-led Medication Reconciliation Service Benefits in Hospitalised Medical Patients · NA · terminated
- NCT04709614 — Psychological Factors That Influence Severity of Allergic Rhinitis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06637280 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University Clinic of Pulmonary and Allergic Diseases Golnik
- Last refreshed: 15 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06637280.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing